Lexaria Bioscience Corp.

CNSX: LXX


Canadian symbol: LXX.CN
US symbol: LXRP

Currency in CAD

Valuation Measures

Market Cap (intraday) 530.15M
Enterprise Value 329.79M
Trailing P/E N/A
Forward P/E 1N/A
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)80.19
Price/Book (mrq)9.31
Enterprise Value/Revenue 379.25
Enterprise Value/EBITDA 6-7.16

Trading Information

Stock Price History

Beta (5Y Monthly) 1.87
52-Week Change 3-35.45%
S&P500 52-Week Change 315.51%
52 Week High 30.9900
52 Week Low 30.3100
50-Day Moving Average 30.4051
200-Day Moving Average 30.4171

Share Statistics

Avg Vol (3 month) 352.77k
Avg Vol (10 day) 395.25k
Shares Outstanding 589.59M
Float 73.79M
% Held by Insiders 119.28%
% Held by Institutions 10.00%
Shares Short (Aug. 13, 2020) 452.09k
Short Ratio (Aug. 13, 2020) 40.79
Short % of Float (Aug. 13, 2020) 40.07%
Short % of Shares Outstanding (Aug. 13, 2020) 40.06%
Shares Short (prior month Jul. 14, 2020) 461.05k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:1
Last Split Date 3Dec. 15, 2015

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Aug. 30, 2019
Most Recent Quarter (mrq)May 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,135.62%

Management Effectiveness

Return on Assets (ttm)-78.74%
Return on Equity (ttm)-135.74%

Income Statement

Revenue (ttm)375.93k
Revenue Per Share (ttm)0.00
Quarterly Revenue Growth (yoy)35.90%
Gross Profit (ttm)192.53k
EBITDA -4.16M
Net Income Avi to Common (ttm)-4.3M
Diluted EPS (ttm)-0.0530
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.05M
Total Cash Per Share (mrq)0.02
Total Debt (mrq)28.76k
Total Debt/Equity (mrq)0.90
Current Ratio (mrq)27.79
Book Value Per Share (mrq)0.04

Cash Flow Statement

Operating Cash Flow (ttm)-2.72M
Levered Free Cash Flow (ttm)-1.06M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LXX.CN
Lexaria Bioscience
1 day ago
LXX.CN
Lexaria Bioscience
1 week ago
LXX.CN
Lexaria Bioscience
1 month ago
LXX.CN
Lexaria Bioscience
2 months ago
LXX.CN
Lexaria Bioscience
3 months ago
LXX.CN
Lexaria Bioscience
3 months ago
LXX.CN
Lexaria Bioscience
4 months ago
LXX.CN
Lexaria Bioscience
4 months ago
LXX.CN
Lexaria Bioscience
4 months ago
LXX.CN
Lexaria Bioscience
5 months ago
LXX.CN
Lexaria Bioscience
5 months ago
LXX.CN
Lexaria Bioscience
6 months ago
LXX.CN
Lexaria Bioscience
6 months ago
LXX.CN
Lexaria Bioscience
6 months ago
LXX.CN
Lexaria Bioscience
6 months ago
LXX.CN
Lexaria Bioscience
8 months ago
LXX.CN
Lexaria Bioscience
8 months ago
LXX.CN
Lexaria Bioscience
8 months ago
LXX.CN
Lexaria Bioscience
9 months ago
LXX.CN
Lexaria Bioscience
9 months ago
LXX.CN
Lexaria Bioscience
9 months ago
LXX.CN
Lexaria Bioscience
9 months ago
LXX.CN
Lexaria Bioscience
9 months ago
LXX.CN
Lexaria Bioscience
9 months ago
LXX.CN
Lexaria Bioscience
10 months ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago
LXX.CN
Lexaria Bioscience
1 year ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
19.28%% of Shares Held by All Insider
0.00%% of Shares Held by Institutions
0.00%% of Float Held by Institutions
0Number of Institutions Holding Shares
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Lexaria Bioscience Corp.


Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation

KELOWNA, BC / ACCESSWIRE / September 16, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, proudly supports the corporate growth initiatives underway by its DehydraTECHTM licensee, Boldt Runners Corporation ("Boldt Runners"), owners of the Cannadips CBD bran... Read More...
Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Lexaria BioScience Receives Ethics Board Approval to Conduct Exploratory Clinical Study using Cannabidiol for Blood Pressure Reduction

Complements previously published data that cites Lexaria's TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure KELOWNA, BC / ACCESSWIRE / July 28, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced that it has received... Read More...
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

KELOWNA, BC / ACCESSWIRE / June 18, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has submitted a grant application to the U.S. National Institutes of Health (NIH) entitled "In vitro and in vivo animal exploratory pharmacokinetic and prelimin... Read More...
Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment

KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria's patented DehydraTECHTM drug delivery te... Read More...
Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

Lexaria Bioscience Begins Coronavirus COVID-19 Drug Delivery Program

KELOWNA, BC / ACCESSWIRE / March 19, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, announces it is commencing a program, in collaboration with leading laboratories in Canada and the USA, to study the benefits of Lexaria's DehydraTECHTM drug delivery platform f... Read More...
Industry Solutions from Lexaria's DehydraTECHTM Hemp and Cannabis Powders

Industry Solutions from Lexaria’s DehydraTECHTM Hemp and Cannabis Powders

KELOWNA, BC / ACCESSWIRE / February 13, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that its DehydraTECHTM-enabled CBD infused powders are now available for sale across the USA to businesses wanting to produce topicals and edibles with clinically p... Read More...
Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

Lexaria Bioscience Corp. and Cannadips Cannabis Announce Expanded Relationship Into Cannabis Oral Pouch & Dip Category

KELOWNA, BC / ACCESSWIRE / January 22, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a new definitive agreement to provide its patented DehydraTECHTM technology to Cannadips' cannabis products, both in its current California market,... Read More...
Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

Lexaria Bioscience Corp. and Cannadips CBD Announce Definitive Technology Licensing agreement for CBD Oral Pouch & Dip Category

KELOWNA, BC / ACCESSWIRE / January 14, 2020 / Lexaria Bioscience Corp. (LXRP)(LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has reached a definitive agreement to provide its patented DehydraTECHTM technology to Cannadips CBD, the Original Smokeless CBD Dip Brand.Cannadips CBD is Ame... Read More...
Hill Street Sees 300% YOY Increase in Holiday Pack Sales and Provides Operational Update

Hill Street Sees 300% YOY Increase in Holiday Pack Sales and Provides Operational Update

Hill Street's Entertainer Pack at major retailers in time for Christmas and New Year'sToronto, Ontario--(Newsfile Corp. - December 23, 2019) - Hill Street Beverage Company Inc. (TSXV: BEER) ("Hill Street" or the "Company"), is pleased to announce the launch of its new Entertainer's Pack of alcohol-free wines has achieved national distribu... Read More...
Pure Ratios CEO Chad Conner Releases 15-Part Video Series on Cannabis Medicine

Pure Ratios CEO Chad Conner Releases 15-Part Video Series on Cannabis Medicine

Pure Ratios Holdings, a subsidiary of 4Front Ventures Corp. (CSE:FFNT.CN)(OTCQX:FFNTF), continues its mission to educate the public on the science of cannabis with a video series about the endocannabinoid systemSAN DIEGO, CA / ACCESSWIRE / November 27, 2019 / Chad Conner, CEO and co-founder of the San Diego cannabis wellness brand, Pure R... Read More...
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Featured in NetworkNewsWire Publication Reporting on Momentous Advances in Drug-Delivery Innovation

NEW YORK, Sept. 05, 2019 -- via NetworkWire — Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities.To view the full publication, titled “Innovative Drug-Delivery Sy... Read More...
Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Lexaria Bioscience Announces DehydraTECH Patent for Pharmaceutical Applications of Cannabinoids to Treat Certain Disease Conditions

Lexaria Bioscience Corp. CONNECT TO Lexaria Bioscience Corp. Tuesday, August 27, 2019 6:15 AM KELOWNA, BC / ACCESSWIRE / August 27, 2019 / Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to an... Read More...
Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

Lexaria Announces Commercial Launch of ChrgD+ Odorless, Flavorless, Water-Soluble Powdered Hemp Oil

KELOWNA, BC / ACCESSWIRE / August 22, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with Dehydra... Read More...
Lexaria's Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

Lexaria’s Appoints Former Altria Group Senior Executive and Operating Company Chief to Board of Directors

KELOWNA, BC / ACCESSWIRE / August 14, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Brian Quigley to its board of directors. Mr. Quigley most recently spent 16 years at Altria Group, with 7 of those years spent as P... Read More...
Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

Lexaria Bioscience Completes Initial Project with Canada’s National Research Council

No chemical modification or degradation of Active Pharmaceutical Ingredients evidenced using DehydraTECH after acidic pH stability testingStrategically significant absence of covalent-bonded New Molecular Entity creation using DehydraTECHKELOWNA, BC / ACCESSWIRE / August 8, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN), (the “Company” o... Read More...
Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

Lexaria Bioscience Engages Integra Consulting Group to Provide Investor Relations Services

KELOWNA, BC / ACCESSWIRE / August 2, 2019 / Lexaria Bioscience Corp. (LXX.CN) (LXRP) (“Lexaria” or the “Company”) announces it has retained Integra Consulting Group LLC (“Integra”) to provide investor relations services to the Company in compliance with regulatory guidelines.Integra partners with select underexposed and undervalued emergi... Read More...
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast on Dramatic Results of CBD Delivery System Study

NEW YORK, June 13, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of an audio press release titled, “Dramatically Improved Delivery Systems Promise More Effective Cannabis Treatments.”To hear the CannabisNewsAudio version, visit: http://cnw.fm/My9kX.To read the full edito... Read More...
Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

Lexaria Bioscience Corp. Featured in CannabisNewsAudio Broadcast Touting Impact of Technology on CBD Edible Space

NEW YORK, May 31, 2019 -- via CannabisNewsAudio – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) today announces the availability of a CannabisNewsAudio Broadcast titled, “Disruptive CBD Delivery Technology Could Revolutionize World of Cannabis Consumer Products, Edibles.”To hear the CannabisNewsAudio version, visit: http://cnw.fm/xJB7... Read More...
Combining Lexaria's DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

Combining Lexaria’s DehydraTECHTM with Nanotech Delivers Increased Quantities of CBD into Brain Tissue

Lexaria's Patented DehydraTECH Combined with Nanoemulsion Formulation Delivers 1,137% More CBD KELOWNA, BC / ACCESSWIRE / May 28, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces recent animal testing proves that combining Lexaria's DehydraTECHTM delivery technolog... Read More...
Lexaria's DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

Lexaria’s DehydraTECH Formulation Delivers 475% More CBD to Bloodstream after 15 Minutes than Conventional Industry Formulations

The DehydraTECH formulation delivered measurable quantities of cannabidiol ("CBD") into blood in as little as 2 minutes;Lexaria's technology delivered more CBD to bloodstream in 15 minutes than conventional medium chain triglyceride ("MCT") oil based control formulation achieved in 60 minutes;The area under the curve ("AUC") for Lexaria's... Read More...
Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options

Lexaria Bioscience Renews Contracts with Senior Management and Cancels Options

KELOWNA, BC / ACCESSWIRE / April 9, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, announces that it has successfully negotiated renewal management contracts with Chief Executive Officer Chris Bunka and President John Docherty.The new contracts are for 3-year terms and... Read More...
Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria's DehydraTECH(TM) Powered TurboCBD(TM) Capsules

Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria’s DehydraTECH(TM) Powered TurboCBD(TM) Capsules

KELOWNA, BC / ACCESSWIRE / February 21, 2019 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the ''Company'' or ''Lexaria''), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical s... Read More...
Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH™ Technology

Altria Group Invests Up to $12M in Lexaria Bioscience’s DehydraTECH™ Technology

KELOWNA, British Columbia, Jan. 17, 2019 -- via NetworkWire -- Lexaria Nicotine LLC, a wholly owned subsidiary of Lexaria Bioscience Corp. (LXRP) (CSE:LXX), has entered into a definitive agreement with Altria Group Inc. (MO) to fund the research & development of Lexaria’s patented DehydraTECH™ technology.Lexaria’s DehydraTECH™ enhance... Read More...
Coming Soon.

Delayed data (1h)
NameAgePositionAppointed
Christopher A. Bunka
Chairman of the Board, Chief Executive Officer
58Chairman of the Board, Chief Executive Officer2017
John Martin Docherty
President, Director
49President, Director2016
Allan Horst Spissinger
Chief Financial Officer
50Chief Financial Officer2018
Ed Ergenzinger
Chief Legal Officer and Senior Vice President - Innovation
--Chief Legal Officer and Senior Vice President - Innovation2018
Nicholas W. Baxter
Independent Director
66Independent Director2011
Ted McKechnie
Independent Director
72Independent Director2019
Brian W. Quigley
Independent Director
46Independent Director2019


Share this page